Avalo Therapeutics, Inc.
AVTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 54.7% |
| R&D Expenses | $14 | $14 | $9 | $8 |
| G&A Expenses | $6 | $5 | $6 | $4 |
| SG&A Expenses | $6 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $19 | $15 | $13 |
| Operating Income | -$19 | -$19 | -$15 | -$13 |
| % Margin | – | – | – | -6,932.8% |
| Other Income/Exp. Net | -$11 | -$1 | $2 | -$22 |
| Pre-Tax Income | -$31 | -$21 | -$13 | -$35 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$31 | -$21 | -$13 | -$35 |
| % Margin | – | – | – | -18,405.7% |
| EPS | -2.19 | -1.92 | -1.25 | 13.89 |
| % Growth | -14.1% | -53.6% | -109% | – |
| EPS Diluted | -2.19 | -1.92 | -1.25 | 10.47 |
| Weighted Avg Shares Out | 14 | 11 | 11 | 10 |
| Weighted Avg Shares Out Dil | 14 | 11 | 11 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$31 | -$19 | -$15 | -$13 |
| % Margin | – | – | – | -6,897.4% |